7 papers in the library · 987 citations · publishing 2018-2026
PsyArXiv March 26, 2026 Broc A. Pagni, Stephen Ross, Sarah E. Mennenga et al. preprint
Safety and Efficacy of Psilocybin-Assisted Therapy for Alcohol Use Disorder: Open-Label Extension of a Phase II Randomized Controlled Trial
March 17, 2026 Lindsey T. Owens preprint
Discussions around the diagnosis and treatment of developmental trauma continue to evolve, yet a growing body of literature highlights its profound impact on physical, emotional, cognitive, and relational functioning. Developmental trauma often involves coping strategies adapted in response to chronic early-life adversity, including physiological and emotional dysregulation, attachment...
Psychology of Addictive Behaviors June 5, 2023 Gabrielle Agin-Liebes, Elizabeth M. Nielson, Michael Zingman et al. 42 citations
OBJECTIVE: The primary aim of this qualitative study was to delineate psychological mechanisms of change in the first randomized controlled trial of psilocybin-assisted psychotherapy to treat alcohol use disorder (AUD). Theories regarding psychological processes involved in psychedelic therapy remain underdeveloped. METHOD: Participants (N = 13) mostly identified as non-Hispanic and White, with...
Contemporary Clinical Trials December 1, 2022 Kelley C O'Donnell, Sarah E. Mennenga, Lindsey T. Owens et al. 24 citations
Several lines of evidence suggest that classic psychedelics (5-HT2A receptor agonists or partial agonists) such as psilocybin might facilitate behavior change in individuals with substance use disorders. We conducted a multi-site, double-blind, randomized controlled trial (RCT) to assess the effects of psilocybin-assisted psychotherapy in alcohol-dependent volunteers. In addition to a...
JAMA Psychiatry August 24, 2022 Michael P. Bogenschutz, Stephen Ross, Snehal Bhatt et al. 668 citations
Importance Although classic psychedelic medications have shown promise in the treatment of alcohol use disorder (AUD), the efficacy of psilocybin remains unknown. Objective To evaluate whether 2 administrations of high-dose psilocybin improve the percentage of heavy drinking days in patients with AUD undergoing psychotherapy relative to outcomes observed with active placebo medication and...
Frontiers in Pharmacology April 3, 2018 Tara C. Malone, Sarah E. Mennenga, Jeffrey Guss et al. 128 citations
A growing body of evidence shows that existential and spiritual well-being in cancer patients is associated with better medical outcomes, improved quality of life, and serves as a buffer against depression, hopelessness, and desire for hastened death. Historical and recent research suggests a role for psilocybin-assisted psychotherapy in treating cancer-related anxiety and depression. A...
Frontiers in Pharmacology February 20, 2018 Michael P. Bogenschutz, Samantha K. Podrebarac, Jessie H. Duane et al. 125 citations
After a hiatus of some 40 years, clinical research has resumed on the use of classic hallucinogens to treat addiction. Following completion of a small open-label feasibility study, we are currently conducting a double-blind placebo-controlled clinical trial of psilocybin-assisted treatment of alcohol use disorder. Although treatment effects cannot be analyzed until the study is complete,...